Trial Profile
A Phase I Study of SGI-110 Combined With Irinotecan Followed by a Randomized Phase II Study of SGI-110 Combined With Irinotecan Versus Regorafenib or TAS-102 in Previously Treated Metastatic Colorectal Cancer Patients
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 03 Apr 2024
Price :
$35
*
At a glance
- Drugs Guadecitabine (Primary) ; Irinotecan (Primary) ; Regorafenib; Tipiracil/trifluridine
- Indications Adenocarcinoma; Colorectal cancer
- Focus Adverse reactions; Therapeutic Use
- 02 Apr 2024 Results (n=96) assessing safety and efficacy from phase II portion of this trial published in the International Journal of Cancer
- 25 Oct 2020 Preliminary results (n=103, data cut off: 14 Nov 2019) presented at the 32nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
- 14 Sep 2020 Results published in the ClinicalTrials.gov Trial Registry